Metabasis, Valeant start HBV Phase II

MBRX said partner VRX started an open-label international Phase II trial of oral remofovir in 220 patients with HBV. The 48-week study will test 5, 10, 20 and 30 mg/day of remofovir or 10 mg/day of He...